We would love to hear your thoughts about our site and services, please take our survey here.
AbbVie is restocking its drug pipeline in a big way, announcing Wednesday an $8.7 billion deal to buy neuroscience-focused Cerevel Therapeutics, just days after agreeing to a similar sized acquisition of the cancer biotechnology company ImmunoGen.
Lilly failing to get enough support for their takeover of Point, not surprised with : Point Biopharma is a developer of radioligand therapy, a targeted cancer treatment which uses a combination of molecules that attach themselves to the tumors and radioactive particles that kill the specific cells.
The company expects results from its late-stage study of experimental therapy, PNT2002, to treat a type of advanced prostate cancer later this month.Expect Point Biopharma’s share price to go north and Avacta’s JV to look even more interested.
Not surprised if Lilly choose to focus on Avacta instead.
Further to Novartis’ investor / strategy day, interesting to note that
The chairman Eliot Foster is taking up a new CEO role as well( today’s RNS), the Chairman clearly aware of potential change of the structure of management of Avacta, with several majors knocking on the door!